| --- | --- | --- | |------------------------------------------------------|-------|-------| | | | | | | | | | | | | | Wave Life Sciences Fourth Quarter and Full Year 2022 | | | | Financial Results and Business Update March 22, 2023 | | | Forward-looking statements 2 This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical st ...

| --- | --- | --- | |------------------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | Wave Life Sciences Third Quarter 2022 Earnings | | | | November 10, 2022 | | | Forward-looking statements 2 This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research an ...

WAVE LIFE SCIENCES Towards the Clinic: Spotlight on RNA Editing for AATD Virtual event | September 28, 2022 Forward-looking statements 2 This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activities and timing there ...

| --- | --- | --- | --- | |-------------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | Wave Life Sciences Second Quarter 2022 Earnings | | | | | August 11, 2022 | | | | Forward-looking statements 2 This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, busine ...

Wave Life Sciences Corporate Presentation May 12, 2022 WAVE Forward-looking statements 2 This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activities and timing thereof, competitive position, potential growth oppor ...

Chemically optimized stereopure oligonucleotides direct ADAR- mediated RNA editing Paloma H Giangrande, PhD Vice President, Platform Discovery Sciences Biology Oligonucleotides & Precision Therapeutics March 15-16, 2022 Forward looking statements 2 This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business str ...

WAVE | --- | --- | --- | --- | --- | --- | |--------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | Wave Life Sciences | | | | | | | Corporate Presentation March 3, 2022 | | | | | | Forward-looking statements 2 This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studi ...

WAVE | --- | --- | --- | --- | --- | --- | --- | |----------------------------|--------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | Third Quarter 2021 | Wave Life Sciences | | | | | | | Earnings November 10, 2021 | | | | | | | Forward-looking statements 2 This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operatio ...

Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update August 5, 2021 Dosing underway in FOCUS-C9 clinical trial of WVE-004 in C9-ALS / C9-FTD – first oligonucleotide using PN backbone chemistry modifications in clinical study Recruitment ongoing for clinical trials in HD and DMD Generating clinical data in multiple trials through 2022 to enable decision making Leading endogenous ADAR editing capability demonstrated restoration of functional AAT protein in vivo; new da ...

| --- | --- | --- | --- | --- | --- | --- | |-------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | Wave Life Sciences | | | | | | | | Corporate Presentation May 13, 2021 | | | | | | | Forward-looking statements 2 This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and ...